Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s HMBD-002 for further clinical development
-
Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response...
-
DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) -- SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for...
-
Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise Strengthened Leadership and Expanded U.S. Presence Positions SynOx...
-
Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused...
-
Wilmington, Delaware, March 20, 2025 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Hepatitis C Testing Market by Technique (Immunoassay, PCR, and Other Techniques), Test...
-
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
-
GUILFORD, Conn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize...
-
CHF 50 Million extension round co-led by Cormorant Asset Management, with participation from other existing investors Proceeds will be used to support the advancement of multiple first-in-class and...
-
Hummingbird Bioscience Licenses Novel Antibodies to Immunome